Abstract: Smac mimetics (SMs) are considered promising cancer therapeutics. However, the mechanisms responsible for mediating cell death by SMs are still only partly understood. Therefore, in this study, we investigated signaling pathways upon treatment with the bivalent SM BV6 using two SM-sensitive breast cancer cell lines as models. Interestingly, genetic silencing of transforming growth factor (TGF)β activated kinase (TAK)1, an upstream activator of the nuclear factor-kappaB (NF-κB) subunit RelA (p65), increased BV6-induced cell death only in EVSA-T cells, although it reduced BV6-mediated upregulation of tumor necrosis factor (TNF)α in both EVSA-T and MDA-MB-231 cells. By comparison, genetic silencing of p65, a key component of canonical NF-κB signaling, blocked BV6-induced cell death in MDA-MB-231 but not in EVSA-T cells. Similarly, knockdown of NF-κB-inducing kinase (NIK) rescued MDA-MB-231 cells from BV6-induced cell death, while it failed to do so in EVSA-T cells. Consistently, silencing of p65 or NIK reduced BV6-stimulated upregulation of TNFα in MDA-MB-231 cells. In conclusion, TAK1, receptor-interacting kinase 1 (RIPK1) as well as canonical and non-canonical NF-κB signaling are differentially involved in SM-induced cell death in breast cancer cells. These findings contribute to a better understanding of SMinduced signaling pathways.
Introduction
Apoptosis, a well-studied form of programed cell death, is often dysregulated in cancer cells, for example, by upregulation of Inhibitor of Apoptosis (IAP) proteins (Brown et al., 2013) . This family of proteins is defined by carrying at least one conserved zinc-binding baculovirus IAP repeat (BIR) domain enabling them to interact with other proteins (Hunter et al., 2007) . Among the seven IAP proteins so far identified in mammals are cellular IAP1 (cIAP1), cIAP2 and X-linked IAP (XIAP) (Fulda and Vucic, 2012) . XIAP is able to directly inhibit caspases-3, -7 and -9, thereby preventing cells from undergoing apoptosis (Deveraux et al., 1997 (Deveraux et al., , 1998 . The E3 ligases cIAP1 and cIAP2 inhibit apoptosis largely by mediating canonical NF-κB activation and retaining the kinase RIPK1 within the tumor necrosis factor (TNF) receptor 1 (TNFR1) complex I (O'Donnell et al., 2007; Bertrand et al., 2008) . This complex is assembled upon binding of the ligand TNFα to TNFR1 which leads to the recruitment of TNFR type 1-associated death domain protein (TRADD), RIPK1, cIAP1/2 and the E3 ligases TNFR-associated factor (TRAF)2 and TRAF5 (Micheau and Tschopp, 2003) . cIAP1/2 then ubiquitinates RIPK1 (Bertrand et al., 2008) , initiating the recruitment of two additional complexes, i.e. the linear ubiquitin chain assembly complex (LUBAC) and the TAK1/TAK1-binding protein (TAB)1/TAB2/3 complex (Brenner et al., 2015) . TAK1 is a major player in the activation of canonical NF-κB signaling downstream of TNFR1, as it recruits and phosphorylates the Inhibitor of NF-κB kinase β (IKKβ), a member of the IKK complex (Wang et al., 2001; Ea et al., 2006) . Apart from IKKβ, this complex also contains IKKα and IKKγ (also known as NF-κB essential modulator/NEMO) and is responsible for phosphorylating the Inhibitor of κB (IκB)α, resulting in its degradation (Chen et al., 1995; Ea et al., 2006) . Once this inhibitor is degraded, the NF-κB subunit RelA (p65), which is usually sequestered in the cytoplasm by IκBα, is free to translocate to the nucleus, forms dimers with itself and other NF-κB subunits and mediates gene expression of a plethora of genes (Zhang et al., 2017) .
Loss of cIAP1/2 or deubiquitination of RIPK1 by the deubiquitinating enzyme cylindromatosis (CYLD) leads to dissociation of RIPK1 from complex I and formation of a secondary complex, called complex II, consisting of RIPK1, TRADD, Fas-associated protein with a death domain (FADD) and caspase-8, which then initiates cell death .
While cIAP1/2 contribute to canonical NF-κB activation, they prevent non-canonical NF-κB activation by degrading NIK via a complex consisting of TRAF2, TRAF3, cIAP1 and cIAP2 (Zarnegar et al., 2008) . Upon cIAP1/2 loss, NIK accumulates and initiates processing of p100 to p52 and its subsequent translocation together with RelB into the nucleus (Zarnegar et al., 2008) .
XIAP, cIAP1 and cIAP2 can be inhibited by the second mitochondria-derived activator of caspases (Smac), an endogenous inhibitor that is released from mitochondria upon disruption of mitochondrial membranes (Du et al., 2000; Verhagen et al., 2000) . Synthetic SMs have been developed that inhibit XIAP and stimulate degradation of cIAP1 and cIAP2 by activating their autoubiquitination (Varfolomeev et al., 2007) . Loss of cIAP1/2 allows RIPK1 to form complex II, initiating RIPK1-and caspase-dependent cell death . In parallel, NIK is no longer degraded by cIAP1/2, accumulates and activates noncanonical NF-κB signaling (Varfolomeev et al., 2007) .
In a gene expression study, we have previously shown that the bivalent SM BV6 induces NF-κB activation, gene expression and TNFR1-dependent cell death in a timedependent manner in the progesterone receptor-positive breast cancer cell line EVSA-T as well as in the triple-negative breast cancer cell line MDA-MB-231 (Schmidt et al., 2018) . The aim of this study was to further elucidate the involved mechanisms upstream as well as downstream of NF-κB activation and the distinct roles of canonical and non-canonical NF-κB signaling in BV6-induced cell death and gene expression in these two SM-sensitive breast cancer cell lines.
Results

BV6 induces RIPK1-mediated cell death in breast cancer cell lines
The kinase RIPK1, as part of the TNFR1 complex I, is one of the most upstream mediators of NF-κB signaling (Brenner et al., 2015) as well as an important regulator of cell death . As SM-induced depletion of cIAP1/2 affects the ubiquitination status of RIPK1, we explored the functional relevance of RIPK1 in BV6-mediated cell death. Genetic silencing of RIPK1 strongly inhibited BV6-induced cell death in both EVSA-T and MDA-MB-231 cells ( Figure 1A,B) . In addition, pharmacological inhibition of RIPK1 kinase activity by Necrostatin-1s (Nec-1s) significantly decreased BV6-induced cell death and abolished cleavage of caspase-3 in both cell lines ( Figure 1C,D) . Consistently, immuno blot analysis revealed increased phosphorylation of RIPK1 upon BV6 stimulation ( Figure 1E ). This demonstrates that BV6-induced cell death in both cell lines depends on the RIPK1 protein and RIPK1 kinase activity. As RIPK3 was not expressed in EVSA-T and MDA-MB-231 cells (data not shown), we did not include RIPK3 in our study.
TAK1 inhibits BV6-induced cell death in EVSA-T cells
TAK1, another protein recruited to the TNFR1 complex I, has been shown to be crucial for activation of the canonical NF-κB signaling pathway (Wang et al., 2001) . NF-κB activation is involved in the upregulation and secretion of TNFα upon BV6 treatment, and TNF auto-/paracrine signaling is required for TNFα/TNFR1-mediated cell death in many cancer cell lines, including MDA-MB-231 (Eckhardt et al., 2014) . As TAK1-induced, TNFR1-mediated NF-κB activation functions downstream of RIPK1, we used genetic silencing of TAK1 to investigate its role in BV6-induced cell death. Interestingly, we found that knockdown of TAK1 using three independent siRNA oligonucleotides significantly increased BV6-induced cell death in EVSA-T cells, but not in MDA-MB-231 cells (Figure 2A ), although TAK1 was silenced to a comparable degree in both cell lines ( Figure 2B ). To investigate whether caspase activity and/or TNFα/TNFR1 auto-/paracrine signaling are required for BV6-induced cell death upon TAK1 knockdown, we used the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) and the TNFα-blocking antibody Enbrel. Addition of either zVAD.fmk or Enbrel completely blocked BV6-induced cell death in EVSA-T upon siRNA-mediated knockdown of TAK1 ( Figure 2C ). Also, Nec-1s significantly reduced BV6-induced cell death in these cells ( Figure 2D ). These results indicate that BV6-induced cell death upon loss of TAK1 depends on caspase activation and TNFα.
p65, a component of canonical NF-κB signaling, is required for BV6-induced cell death in MDA-MB-231 cells
As our results indicate that RIPK1 and TAK1, known as upstream activators of the canonical NF-κB pathway, (A) Cells were transfected with 10 nm non-targeting (siCtrl) siRNA or siRNA against RIPK1 for 48 h and then treated with 2.5 nm BV6 (EVSA-T) or 50 nm BV6 (MDA-MB-231) for 48 h. Cell death was assessed by PI staining using flow cytometry. Mean and standard deviation (SD) of three independent experiments performed in duplicates are shown; *p < 0.05, **p < 0.01. (B) Cells were transfected with 10 nm nontargeting siRNA or siRNA against RIPK1 for 48 h. Expression levels of RIPK1 were analyzed using Western blotting. GAPDH was used as loading control. (C) Cells were treated with 1 μm Nec-1s and the indicated concentrations of BV6 for 48 h. Cell death was assessed by PI staining using flow cytometry. Mean and SD of three independent experiments performed in duplicates are shown; *p < 0.05, **p < 0.01. (D) Cells were preincubated with 10 μm Nec1s for 1 h and then treated with 5 nm BV6 (EVSA-T) or 50 nm BV6 (MDA-MB-231) for 8 h. Cleavage of caspase-3 was determined by Western blotting, Vinculin was used as loading control. One representative experiment out of two is shown. (E) Cells were preincubated with 10 μm Nec1s for 1 h and then treated with 5 nm BV6 (EVSA-T) or 50 nm BV6 (MDA-MB-231) for 8 h. Protein levels of phospho-RIPK1 (p-RIPK1) and RIPK1 were determined by Western blotting, Vinculin was used as loading control. One representative experiment out of two is shown.
differentially affect SM-induced cell death, we asked whether RIPK1 and TAK1 exert their effects on SMinduced cell death through canonical NF-κB signaling. Genetic silencing of the NF-κB subunit p65 (RelA), a key component of canonical NF-κB signaling, significantly decreased BV6-induced cell death in MDA-MB-231 cells, but failed to prevent BV6-mediated cell death in EVSA-T cells ( Figure 3A,B) . To test whether residual TNFα in p65 knockdown EVSA-T cells may contribute to BV6-induced cell death we treated control and p65 knockdown cells with the TNFα-blocking antibody Enbrel. Enbrel significantly reduced BV6-induced cell death in p65 knockdown EVSA-T cells ( Figure 3C ), suggesting that TNFα signaling contributes to BV6-induced cell death in this context. This set of experiments indicates that BV6-induced cell death depends on canonical NF-κB signaling in MDA-MB-231 cells.
Non-canonical NF-κB signaling is involved in BV6-mediated cell death in MDA-MB-231 cells
To explore the involvement of non-canonical NF-κB signaling we assessed the stabilization of NIK protein, a key (A) Cells were transfected twice with 10 nm non-targeting siRNA or siRNA against TAK1 for 48 h and then treated with indicated concentrations of BV6 for 24 h (EVSA-T) or 48 h (MDA-MB-231). Cell death was assessed by PI staining using flow cytometry. Mean and SD of four (EVSA-T) and three (MDA-MB-231) independent experiments performed in duplicates are shown. (B) Cells were transfected twice with 10 nm non-targeting siRNA or siRNA against TAK1 for 48 h. Expression levels of TAK1 were analyzed using Western blotting with GAPDH as loading control. (C, D) EVSA-T cells were transfected twice with 10 nm non-targeting siRNA or siRNA against TAK1 for 48 h and then treated with 5 nm BV6, 50 μg/ml Enbrel, 20 μm zVAD.fmk for 24 h (C) or pre-treated with 1 μm Nec-1s for 1 h and then 2.5 nm BV6 for another 24 h (D). Cell death was assessed by PI staining using flow cytometry. Mean and SD of three independent experiments performed in duplicates are shown. *p < 0.05, **p < 0.01.
upstream kinase involved in non-canonical NF-κB signaling that is tightly regulated by cIAP1/2 (Zarnegar et al., 2008) . NIK accumulated within 2 h of treatment with BV6 in MDA-MB-231 cells, while no accumulation of NIK protein upon addition of BV6 was detectable in EVSA-T cells ( Figure 4A ). Consistently, genetic silencing of NIK reduced BV6-induced cell death in MDA-MB-231 cells but did not affect cell death in EVSA-T cells ( Figure 4B,C) . The ability of different siRNA sequences to inhibit BV6-induced cell death correlated with their ability to silence NIK ( Figure 4B,C) . This suggests that non-canonical NF-κB signaling is involved in BV6-mediated cell death in MDA-MB-231 cells. (A) Cells were transfected twice with 15 nm non-targeting siRNA or siRNA against p65 for 48 h and then treated with 2.5 nm BV6 (EVSA-T) or 50 nm BV6 (MDA-MB-231) for 48 h. Cell death was assessed by PI staining using flow cytometry. Mean and SD of three independent experiments performed in duplicates are shown. (B) Cells were transfected twice with 15 nm non-targeting siRNA or siRNA against p65 for 48 h. p65 expression levels were analyzed by Western blotting with GAPDH as a loading control. (C) Cells were transfected twice with 15 nm non-targeting siRNA or siRNA against p65 for 48 h followed by a preincubation with 50 μg/ml Enbrel for 1 h and subsequent treatment with 2.5 nm BV6 (EVSA-T) or 50 nm BV6 (MDA-MB-231) for 48 h. Cell death was assessed by PI staining using flow cytometry. Mean and SD of three independent experiments performed in triplicates are shown; *p < 0.05, **p < 0.01.
Differential involvement of canonical and noncanonical NF-κB signaling in BV6-stimulated upregulation of TNFα mRNA expression
Next, we explored whether canonical and non-canonical NF-κB signaling is involved in the transcriptional regulation of the prototypic NF-κB target gene TNFα. Stimulation with BV6 upregulated mRNA levels of TNFα, which was reduced by knockdown of TAK1 in both EVSA-T and MDA-MB-231 cells ( Figure 5A ). There was still a substantial upregulation of TNFα mRNA in BV6-treated EVSA-T cells subjected to TAK1 knockdown (approximately 20-fold increase compared to control siRNA-treated cells, Figure 5A ), consistent with the ability of Enbrel to reduce BV6-induced cell death in TAK1 knockdown EVSA-T cells ( Figure 2C ). To investigate whether other death-inducing ligands such as TNF-related apoptosis-inducing ligand (TRAIL) or CD95 ligand (CD95L) could compensate for TNFα in BV6-treated MDA-MB-231 TAK1 knockdown cells we used TRAIL-or CD95L-blocking antibodies. Neither TRAIL-nor CD95L-blocking antibodies had an effect on BV6-induced cell death in TAK1 knockdown cells (Supplementary Figure 1A) , while control experiments confirmed the functionality of the blocking antibodies (Supplementary Figure 1B,C) . Furthermore, p65 knockdown significantly decreased the BV6-stimulated increase in TNFα mRNA levels in both EVSA-T and MDA-MB-231 cells ( Figure 5B, Supplementary Figure 2A) . Silencing of NIK reduced upregulation of TNFα upon BV6 treatment in MDA-MB-231 but not in EVSA-T cells ( Figure 5C , Supplementary Figure 2B ). Together, these findings indicate that both canonical and non-canonical NF-κB signaling are involved in BV6-stimulated upregulation of TNFα in MDA-MB-231 cells, while EVSA-T cells largely rely on canonical NF-κB signaling.
Discussion
SMs are being tested as cancer therapeutics because of their ability to induce cell death and to sensitize cancer cells to chemotherapeutics (Rathore et al., 2017) . However, a number of recent studies have also described a cell type-specific effect on gene expression and upregulation of pro-inflammatory signals prior or in parallel to the induction of cell death (Emeagi et al., 2012; Lecis et al., 2013; Lindemann et al., 2015; Marschall and Fulda, 2015) , underscoring the need for a better understanding of SMinduced signaling.
In the present study, we therefore investigated the involvement of key components of TNFR1 and NF-κB signaling upon BV6-induced cell death using the triple-negative breast cancer cell line MDA-MB-231 and the progesteronereceptor-positive cell line EVSA-T as SM-sensitive cancer cell models. Here, we show that the two cell lines exhibited marked differences in BV6-induced signaling. Interestingly, we identified TAK1 as a negative regulator of BV6-induced cell death in EVSA-T cells using sublethal conditions. In addition, we showed that TAK1 is involved in BV6-stimulated upregulation of TNFα, a central mediator of BV6-induced cell death. Of note, the residual TNFα production in EVSA-T cells upon knockdown of TAK1 was required for BV6-induced cell death, as the addition of the TNFα-blocking antibody Enbrel prevented cell death in BV6-treated TAK1 knockdown cells. This indicates that TAK1 controls both anti-and proapoptotic signaling events in EVSA-T cells and that TAK1 silencing may shift the balance towards cell death. The TAK1/IKK-mediated phosphorylation-dependent functions of RIPK1 could be a possible explanation for the increased cell death observed in TAK1-depleted cells, as TAK1 has been reported to regulate activation of the IKK complex (Wang et al., 2001; Ea et al., 2006) . Within the TNFR1 complex I, RIPK1 is phosphorylated by the IKK complex (Ting and Bertrand, 2016) , which prevents its release from the TNFR1 complex. Loss of TAK1 shuts off IKK activation, allowing unphosphorylated RIPK1 to separate from the TNFR1 complex and to form a cell death-inducing complex together with FADD and caspase-8 (Dondelinger et al., 2013; Ting and Bertrand, 2016) , thereby initiating RIPK1-and caspasedependent cell death. In contrast to EVSA-T cells, knockdown of TAK1 in MDA-MB-231 cells had no effect on cell death induced by BV6. Therefore, MDA-MB-231 cells likely undergo BV6-induced cell death upon TAK1 knockdown in a TNFα-independent manner, as BV6-stimulated upregulation of TNFα is largely blunted in TAK1 knockdown MDA-MB-231 cells. Our data showing that both TRAIL-and CD95L-blocking antibodies failed to block BV6-induced cell death in TAK1 knockdown MDA-MB-231 cells indicate that additional mediators may be involved in this context. Furthermore, our study unravels a differential contribution of different NF-κB signaling branches to BV6-induced cell death. While elements of canonical and non-canonical NF-κB signaling were required for cell death by BV6 in MDA-MB-231 cells, genetic silencing of either p65 or NIK failed to protect EVSA-T cells from BV6-triggered cell death. Consistently, NIK protein accumulated upon exposure to BV6 in MDA-MB-231 cells, but not in EVSA-T cells. A possible explanation for the failure of p65 knockdown to protect EVSA-T cells from cell death by BV6 may be linked to its inability to completely block BV6-stimulated upregulation of TNFα. This p65-independent upregulation of TNFα upon treatment with BV6 might be due to a functional redundancy of NF-κB subunits, as p105/p50 (NFKB1) and cRel (REL) homo-or heterodimers may also contribute to the expression of canonical NF-κB target genes such as TNFα. REL has been reported to be upregulated in p65 knockdown or knockout cells (Hoffmann et al., 2003; Eckhardt et al., 2014) . Also, we recently reported that BV6 stimulates gene expression of REL and NFKB1 in cancer cells including EVSA-T cells (GEO ID: GSE107912; Schmidt et al., 2018) . Another possible explanation is that other transcription factors besides NF-κB mediate upregulation of TNFα in p65 knockdown cells, for example, interferon-regulatory factor (IRF)1 or activator protein (AP)-1, which have also been implied in regulating TNFα expression (Falvo et al., 2010; Eckhardt et al., 2014) .
In summary, this study provides new insights into the context-dependent regulation of BV6-induced signaling pathways even among BV6-sensitive cancer cell lines which might be exploited to increase the sensitivity to SM as cancer therapeutics.
Materials and methods
Cell culture and chemicals
MDA-MB-231 cells obtained from ATCC (American Type Culture Collection, CEM, Manassas, VA, USA) and EVSA-T cells from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) were grown in Dulbecco's Modified Eagle Medium (DMEM) (Life Technologies, Inc., Eggenstein, Germany), supplemented with 10% fetal calf serum (FCS) (Life Technologies, Inc.), 1% penicillin/streptomycin (Life Technologies, Inc.) and 1% sodium pyruvate (Life Technologies, Inc.). Cell lines were authenticated by short tandem repeat (STR) profiling and negatively tested for mycoplasma contamination. BV6 was a kind gift from Genentech, Inc. (San Francisco, CA, USA), Enbrel from Pfizer (Berlin, Germany). zVAD.fmk was purchased from Bachem (Heidelberg, Germany), Nec-1s from Calbiochem, Merck (Darmstadt, Germany) and all other chemicals from Sigma-Aldrich (Taufkirchen, Germany) or Carl Roth (Karlsruhe, Germany), unless indicated otherwise.
siRNA transfection
Cells were transfected with Silencer Select siRNA (Invitrogen, Karlsruhe, Germany): non-silencing control siRNA (no. 4390844) or targeting siRNA (s11914 and s11915 for p65; s17187, s17188 and s17189 for NIK; s16651 and s16653 for RIPK1; s13766 and s13768 for TAK1) using Lipofectamine RNAi MAX (Invitrogen) and OptiMEM (Life Technologies, Inc.). For NIK and RIPK1 knockdown, cells were transfected once with 10 nm siRNA. For knockdown of TAK1 and p65, cells were transfected twice with 10 nm (TAK1) or 15 nm (p65) on two consecutive days. Treatments were performed 48 h after transfection.
Western blotting
Cells were lysed using a Triton X-100 lysis buffer containing 30 mm TrisHCl (Carl Roth, Karlsruhe, Germany), 150 mm NaCl (Carl Roth), 10% Glycerol (Carl Roth), 0.5 mm PMSF (Carl Roth), 2 mm DTT (Millipore, Darmstadt, Germany), 1% Triton X-100 (Carl Roth), 1 × Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany). For detection of TAK1, cells were lysed using CHAPS (Sigma-Aldrich, Taufkirchen, Germany) lysis buffer [1% CHAPS, 30 mm Tris pH 7.5, 150 mm NaCl, 1 × Protease Inhibitor Cocktail (Roche Diagnostics)]. The following antibodies were used for detection: Rabbit anticaspase-3, rabbit anti-phospho RIPK1, rabbit anti-NIK and rabbit anti-TAK1 from Cell Signaling (Beverly, MA, USA), rabbit anti-RIPK1 from BD Biosciences, rabbit anti-p65 from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), mouse anti-GAPDH from HyTest (Turku, Finland) and mouse anti-Vinculin from Merck (Darmstadt, Germany). Horseradish peroxidase (HRP)-conjugated antibodies (goat anti-mouse IgG, goat anti-rabbit IgG; both from Santa Cruz Biotechnologies) were used for detection by enhanced chemiluminescence (Amersham Bioscience, Freiburg, Germany). Representative blots of two independent experiments are shown.
Cell death analysis
Propidium iodide (PI) (Sigma) uptake was measured using flow cytometry (FACS Canto II, BD Biosciences, Heidelberg, Germany) to assess plasma membrane integrity as a parameter of cell death.
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted using the peqGOLD Total RNA kit from Peqlab Biotechnologie GmbH (Erlangen, Germany) according to the manufacturer's instructions. One microgram of RNA was synthesized into the corresponding cDNA using RevertAid H Minus First Strand cDNA Synthesis Kit with random primers (MBI Fermentas GmbH, St. Leon-Rot, Germany) and the peqGOLD DNAse I digestion kit from Peqlab Biotechnologie GmbH, both according to the manufacturer's protocol. For quantification of gene expression levels, SYBR-green based quantitative real-time PCR (Applied Biosystems, Darmstadt, Germany) was performed using the QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems). Primers are listed in Supplementary Table 1 . TNFα mRNA levels were assessed by TaqMan Gene Expression Assay (Life Technologies, Hs01113624_g1) according to the manufacturer's protocol. Data were normalized on 28S-rRNA expression as reference. Melting curves were assessed to control the specificity of the amplified products. Relative expression levels of the gene transcripts were calculated using the ΔΔC t -method.
Statistical analysis
Statistical significance was assessed by Student's t-test (two-tailed distribution, two-sample, equal variance) using Microsoft Excel (Microsoft Deutschland GmbH, Unterschleißheim, Germany); *p-value < 0.05; **p-value < 0.01.
